
Pepto-Bismol is owned by Procter & Gamble (P&G), a publicly traded American multinational consumer goods corporation that trades on NYSE under ticker PG. P&G acquired Pepto-Bismol through its purchase of Norwich Eaton Pharmaceuticals in 1982. Pepto-Bismol is marketed as an over-the-counter remedy for nausea, heartburn, indigestion, upset stomach, and diarrhea, and generated over $300 million in annual US sales as of 2025.
Parent Company
Acquired
1982
Status
Publicly Traded
Headquarters
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Pepto-Bismol | Procter & Gamble Company | Wholly owned |
Pepto-Bismol was originally created in the early 1900s by a doctor in Norwich, New York, as a remedy for cholera infantum, a severe form of diarrhea that affected infants. The original formula was called Bismosal mixture and was first manufactured by Norwich Pharmacal Company. In 1919, the formula was renamed Pepto-Bismol, and the brand began broader marketing as a remedy for various gastrointestinal ailments.
The Norwich Pharmacal Company manufactured and distributed the product through the mid-20th century, building a reputation for effectiveness in treating multiple digestive symptoms. The brand's five-symptom positioning, covering nausea, heartburn, indigestion, upset stomach, and diarrhea, distinguished it from single-symptom competitors.
In 1982, Procter & Gamble acquired Norwich Eaton Pharmaceuticals, the pharmaceutical division of Norwich Pharmacal Company. The acquisition brought Pepto-Bismol into P&G's portfolio, where it has been marketed as part of the company's Personal Health Care division. P&G's marketing expertise and distribution network significantly expanded Pepto-Bismol's reach in the US market.
Under P&G's ownership, Pepto-Bismol became known for its advertising jingle listing the five symptoms it treats. The jingle became a cultural reference point and is considered one of the most recognized advertising campaigns in over-the-counter drug marketing. The brand expanded its product line to include Pepto-Bismol Liquid, Pepto-Bismol Chewable Tablets, and Pepto-Bismol Ultra, with flavor options including cherry and mint.
In recent years, Pepto-Bismol has faced increased competition from generic bismuth subsalicylate products as well as from other gastrointestinal remedies like H2 blockers and proton pump inhibitors. The brand has maintained market position through brand recognition and P&G's marketing support. As of 2025, Pepto-Bismol generated over $300 million in annual US sales, making it one of the leading over-the-counter gastrointestinal remedies by revenue.
Procter & Gamble delivered mixed financial results in fiscal 2026, reflecting both the strength of its business model and challenges in the current consumer environment. In Q2 2026, P&G reported adjusted earnings per share of $1.88, exceeding Wall Street expectations of $1.86, while revenue of $22.21 billion fell slightly short of analyst expectations of $22.28 billion. The company's ability to beat earnings estimates despite revenue challenges demonstrates the effectiveness of its productivity initiatives and cost management strategies.
Financial Performance Overview shows P&G's resilience in a challenging market. The company revised its fiscal 2026 earnings outlook to 1% to 6% net earnings per share growth, down from the previous forecast of 3% to 9%, citing higher restructuring charges. Despite this adjustment, P&G maintained its sales growth guidance, reflecting confidence in its business fundamentals and strategic positioning. CFO Andre Schulten noted that "We've now completed what we fully expect will be the softest quarter of the fiscal year," indicating anticipation of improved performance in the second half.
Volume Performance revealed significant challenges across key categories, with overall volume falling 1% as three out of five product categories reported shrinking volume. This decline reflects broader consumer behavior patterns as inflation-weary consumers hunt for deals and reduce discretionary spending, particularly in P&G's largest market, the United States. Despite these challenges, Schulten emphasized that "People have not stopped washing their hair, they still buy diapers, they do their laundry — albeit at a little bit slower pace, so the market growth has certainly slowed over the last 18 to 24 months."
Segment Performance showed divergent trends across P&G's business portfolio. The baby, feminine and family care segment experienced the steepest decline with volume falling 5% in Q2 2026, facing tough comparisons with the year-ago period when retailers and consumers stocked up ahead of expected port strikes. The grooming business, which includes Gillette and Venus razors, reported a 2% volume drop, reflecting ongoing competitive pressures in the men's grooming market. The health-care segment saw volume fall 1%, including brands like Oral-B, Vicks, and Pepto-Bismol.
Bright Spots in Performance were primarily in the beauty segment, which was the only division to report volume growth, rising 3% fueled by stronger demand for hair-care products. The fabric and home-care business, which includes brands like Febreze and Tide, reported unchanged volume, demonstrating stability in P&G's largest business segment by revenue. These performance variations highlight the importance of P&G's diversified portfolio strategy in navigating market challenges.
Q1 2026 Results demonstrated stronger performance compared to Q2, with net sales of $22.4 billion, up 3% versus the prior year, and organic sales increasing 2%. The company achieved diluted EPS of $1.95 (up 21% YoY) and core EPS of $1.99 (up 3% YoY), reflecting strong operational execution. Operating cash flow was $5.4 billion, and the company returned $3.8 billion to shareholders through dividend payments and share repurchases, demonstrating P&G's commitment to shareholder returns.
Consumer Market Dynamics continue to shape P&G's performance, with the company facing "softer consumer markets, aggressive competition, and a dynamic geopolitical landscape" according to CFO Schulten. These challenges reflect broader economic pressures affecting consumer spending patterns and competitive intensity in key categories. However, P&G expects stronger results in the second half of the fiscal year, fueled by upcoming innovation and improved market conditions.
Innovation and Demand Creation remain central to P&G's strategy for driving growth. The company is increasing investment in innovation and demand creation to improve value for consumers and drive category growth. This focus on innovation is particularly important in the beauty segment, where new product development and marketing initiatives have helped drive volume growth despite overall market challenges.
Q3 2026 Results showed a significant acceleration in performance. P&G reported net sales of $21.24 billion, up 7% versus the prior year, beating Wall Street expectations of $20.5 billion. Organic sales increased 3%, driven by a 2% increase in volume — the first time in a year that P&G reported growing volume across the company. Core EPS of $1.59 beat estimates of $1.56, up 3% YoY. Diluted EPS was $1.63, up 6%, boosted by a gain from the dissolution of the Glad joint venture business. CEO Shailesh Jejurikar stated: "We delivered a solid acceleration in top-line results in our fiscal third quarter, with broad-based growth across product categories and regions." All five segments posted net sales growth: Beauty +11% ($3.87B), Fabric & Home Care +7% ($7.4B), Baby/Feminine/Family Care +6% ($5.06B), Health Care +7% ($3.07B), and Grooming +7% ($1.61B). The company returned $3.2 billion to shareholders via $2.5 billion in dividends and over $600 million in share repurchases. However, P&G warned about uncertainty from the Iran war's effects on input costs and consumer spending, projecting approximately $400 million in after-tax tariff costs and $150 million in commodity cost headwinds. If Brent crude stays around $100/barrel, P&G projects an annual after-tax headwind of $1 billion. The company will not provide a fiscal 2027 forecast until its July earnings report.
Leadership Transition Impact represents a significant element of P&G's current strategy. Shailesh Jejurikar's appointment as CEO effective January 1, 2026, brings fresh perspectives while maintaining continuity through Jon Moeller's transition to Executive Chairman. Jejurikar described his vision at the CAGNY Conference: leveraging P&G's strengths to "create the CPG company of the future."
Geographic Performance varied across P&G's global markets, with the United States facing particular challenges due to consumer behavior changes and competitive pressures. However, the company's global diversification provides stability, with different regions experiencing varying levels of economic pressure and consumer demand patterns.
Supply Chain and Operations have been optimized to support P&G's productivity initiatives and cost management strategies. The company's integrated supply chain encompasses suppliers, manufacturing partners, and retailers in complex networks ensuring product availability worldwide while maintaining operational efficiency.
Future Outlook remains cautiously optimistic, with P&G maintaining its fiscal year 2026 guidance for all-in sales growth of 1% to 5% and net EPS growth of 1% to 6% versus FY2025 diluted EPS of $6.51. Core EPS growth guidance is in-line to up 4% versus FY2025 core EPS of $6.83, equating to $6.83 to $7.09 per share. However, earnings are expected to trend toward the lower end of the range as cost headwinds persist and investments step up. The company faces approximately $400 million in after-tax tariff costs and $150 million in commodity cost headwinds. P&G will not provide a fiscal 2027 forecast until its July 2026 earnings report, citing uncertainty from the Iran war's impact on input costs and consumer spending.
Investor Confidence remained strong despite mixed results, with P&G shares rising more than 2% in morning trading following the Q2 earnings announcement. This positive market response reflects investor confidence in P&G's ability to navigate current challenges while positioning for future growth through strategic initiatives and operational excellence.
P&G's recent performance demonstrates the company's ability to maintain profitability and shareholder returns while navigating challenging market conditions. The combination of operational efficiency, brand strength, and strategic focus on innovation provides a solid foundation for continued success in the competitive consumer goods industry.
Pepto-Bismol is manufactured at P&G facilities that adhere to FDA pharmaceutical manufacturing regulations and P&G's environmental standards. P&G has set goals to reduce Scope 1 and Scope 2 greenhouse gas emissions by 50% by 2030 and achieve net zero emissions by 2040. The company has invested in renewable energy projects and energy efficiency improvements across its manufacturing facilities.
P&G aims to make 100% of its packaging recyclable or reusable by 2030. Pepto-Bismol packaging has been optimized to reduce material usage while maintaining product safety and efficacy. The company has explored alternative packaging materials to further reduce environmental impact.
P&G maintains ethical sourcing programs through its Supplier Sustainability Guidelines, which cover environmental performance, labor practices, and business ethics. All ingredients and materials used in Pepto-Bismol must meet these standards. P&G's supply chain responsibility programs help ensure that bismuth subsalicylate and other ingredients are sourced responsibly.
As an FDA-regulated over-the-counter drug, Pepto-Bismol is subject to rigorous safety and efficacy standards. P&G maintains pharmacovigilance programs to monitor adverse events and reports to FDA as required. The brand's labeling transparently communicates potential side effects, including the temporary darkening of the tongue and stools that can occur with bismuth subsalicylate use.
P&G has established programs to improve access to healthcare products in underserved communities, including donations of over-the-counter health products to disaster relief and community health organizations.
Pepto-Bismol's advertising jingle listing its five treated symptoms has been recognized by advertising industry organizations as one of the most effective and memorable campaigns in over-the-counter drug marketing. The campaign has been acknowledged for its clarity, memorability, and consumer impact.
As a brand with over 100 years of history, Pepto-Bismol has been recognized for sustained market presence and consumer trust. Consumer surveys and brand trust rankings have consistently placed Pepto-Bismol among the most trusted over-the-counter health brands in the United States.
P&G, as parent company, has been recognized as one of the World's Most Admired Companies by Fortune magazine and has received the Ethisphere Institute's World's Most Ethical Companies designation. These corporate recognitions reflect the governance and values that support all P&G brands including Pepto-Bismol.
Pepto-Bismol contains bismuth subsalicylate, which releases salicylate into the body. This raises concerns for individuals with salicylate sensitivity, including those sensitive to aspirin. Due to the salicylate content, Pepto-Bismol is generally not recommended for children or teenagers recovering from viral infections because of the risk of Reye's syndrome, a rare but serious condition. The CDC and FDA have issued guidance on this contraindication, and P&G includes appropriate warnings on product labeling.
Pepto-Bismol can cause temporary and harmless darkening of the tongue and stools. While this side effect is well-documented and harmless, it has caused concern among consumers who were not aware of it. P&G has addressed this through improved labeling and consumer education.
The brand can interact with certain medications, including blood thinners, diabetes medications, and medications for gout and arthritis. These interactions can affect the efficacy of other drugs or increase the risk of side effects. P&G addresses these concerns through comprehensive drug interaction labeling and pharmacist education.
Pepto-Bismol faces significant competitive pressure from generic bismuth subsalicylate products, which offer the same active ingredient at lower price points. This competition has put pressure on Pepto-Bismol's market share and pricing, requiring P&G to invest in brand differentiation through marketing and product format innovation.
The brand's limited international availability has constrained its global growth potential. In some countries, bismuth subsalicylate products are not available or are marketed under different brand names, limiting Pepto-Bismol's reach outside the United States.
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Procter Gamble | USA | 1890 | Mass market | Global | Unisex |
Market Positioning: Pepto-Bismol competes with 1 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Looking for brands with different ownership structures? These similar brands are not owned by Procter & Gamble Company, giving you alternative choices that support different corporate structures.
Beauty Personal CareOwned by Evyap
Turkish brand of men's grooming and shaving products manufactured and marketed by Evyap, known for affordable quality shaving soaps.
Arko is privately owned, unlike Pepto-Bismol which is under a publicly traded parent company.
Beauty Personal CareOwned by Nexus Capital Management
American direct-to-consumer razor and grooming brand known for its subscription model and viral marketing.
Dollar Shave Club is privately owned, unlike Pepto-Bismol which is under a publicly traded parent company.
Beauty Personal CareOwned by Evyap
Turkish beauty and bath soap brand manufactured by Evyap. Sold in over 100 countries. Known for natural ingredients including olive oil, shea butter, and coconut. Market leader in Eastern Europe and Central Asia.
Duru is privately owned, unlike Pepto-Bismol which is under a publicly traded parent company.
Beauty Personal CareOwned by Evyap
Mass-market soap and personal care brand owned by Evyap, sold in over 100 countries with strong positions in Eastern Europe and the Middle East.
Fax is privately owned, unlike Pepto-Bismol which is under a publicly traded parent company.
Beauty Personal CareOwned by Evyap
Men's personal care and grooming brand owned by Evyap, a privately held Turkish personal care company founded in 1927. Gibbs offers shaving products, deodorants, and grooming items primarily in European, Middle Eastern, and Central Asian markets.
Gibbs is privately owned, unlike Pepto-Bismol which is under a publicly traded parent company.
Beauty Personal CareOwned by Great Clips, Inc.
Value hair salon franchise brand owned by Great Clips, Inc. and operated through more than 4,400 franchisee-owned salons.
Great Clips is privately owned, unlike Pepto-Bismol which is under a publicly traded parent company.
Discover popular brands and companies in the Beauty & Personal Care category and related searches from other users.

Italian luxury fragrance and grooming brand founded in Parma in 1916, owned by LVMH since 2001. Known for its signature Colonia fragrance and a full range of home and lifestyle products made in Italy.

Turkish antibacterial soap and personal hygiene brand owned by Evyap, one of Turkey's largest consumer goods manufacturers. Activex uses silver ion technology and is sold primarily in Turkey and Middle Eastern markets.

Procter & Gamble's feminine hygiene brand launched in 1983, holding approximately 27% global market share in menstrual pads and sold in more than 100 countries.